Wanwimolruk S, Edwards G, Ward S A, Breckenridge A M
Department of Pharmacology and Therapeutics, University of Liverpool, UK.
J Pharm Pharmacol. 1992 Nov;44(11):940-2. doi: 10.1111/j.2042-7158.1992.tb03243.x.
The binding of the novel antimalarial drug, arteether, to human plasma, pure albumin and alpha 1-acid glycoprotein has been investigated by ultrafiltration, using [14C]arteether. The protein binding in plasma obtained from 11 healthy male subjects ranged from 73.4 to 81.8% bound, with a mean of 78.7 +/- 2.1%. The binding of drug in plasma was mainly accounted for by binding to albumin and alpha 1-acid glycoprotein. Scatchard analysis of the binding data revealed that the binding affinity of arteether to alpha 1-acid glycoprotein is much greater (20-fold) than that to albumin. This suggests that alpha 1-acid glycoprotein is the more important binding protein in plasma. This may have clinical importance due to alterations in plasma protein binding in patients with malaria, as the concentration of alpha 1-acid glycoprotein is markedly increased during malarial infection.
采用[14C]蒿甲醚,通过超滤法研究了新型抗疟药蒿甲醚与人体血浆、纯白蛋白及α1-酸性糖蛋白的结合情况。从11名健康男性受试者获取的血浆中,药物的蛋白结合率在73.4%至81.8%之间,平均为78.7±2.1%。血浆中药物的结合主要是由于与白蛋白和α1-酸性糖蛋白的结合。对结合数据进行Scatchard分析表明,蒿甲醚与α1-酸性糖蛋白的结合亲和力比与白蛋白的结合亲和力大得多(20倍)。这表明α1-酸性糖蛋白是血浆中更重要的结合蛋白。由于疟疾患者血浆蛋白结合情况发生改变,这可能具有临床意义,因为在疟疾感染期间α1-酸性糖蛋白的浓度会显著升高。